An experimental drug from Novartis AG shrank tumors in more than half of patients with a rare form of lung cancer in an earlystage study that illustrates how genomic data is reshaping pharmaceutical development and cancer care The drug called ceritinib targets an anomaly in a gene called ALK that plays a crucial role in about  of cases of nonsmall cell lung canceror about  patients annually in the US Ceritinib
  